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In order to determine whether the neoplastic T cells 
from patients with cutaneous T-cell lymphoma ex-
press tumor-specific antigens that can serve as the 
targets of an immune response, we took advantage of 
family-specific monoclonal antibodies, magnetic 
bead technology, and recombinant cytokines, which 
provided the previously precluded ability to isolate 
and expand populations of purified tumor and autol-
ogous (.:D8 cytotoxic T cells. Four patients with 
advanced cutaneous T -cell lymphoma had CD8 cells 
that specifically killed autologous tumor in a class I 
limited fashion. Tumor cell cytolysis could be specif-
ically enhanced by pre-culture with autologous 1'-ir-
C utaneous T -ce lJ lymph o ma (CTCL) is a rela tively commo n clona l mali gnancy of "cu taneo us T ce ll s" that express a memory (CD4SR.o) he lper/ inducer (CD4) phenotype and have a di stin ctive tendency to localize in the epidermis (Edelson el ai , 1979; Edel-
son, 19S0; Nickolo fF and Griffith s, 1990; Terbun e ;md Cooper, 
1(93). Like their no rmal cO llnterparts, CTCL ceIJs regularl y displa y 
the "cutaneo us lymphoid antigen, " the ligand for endothelial-
le uk ocyte cell ad hesion 1110lecul e-1 expressed by de rmal e ndothe-
lial cell s in inflamed skin (Pi cker el ai, 1 (90) . Expression of 
cu ta neo us Iymphiod antigen CLA ma y contdbute to the propensity 
of these m ali gnant cells to home to the epid()rmis during the early 
stages of the disease (Picker 1'1 ai, 1991). 
As part of the natura'! course ofCTCL, progressively more poorly 
diffe rentiated and aggressive su bcl o nes of m alignan t cells becom e 
dominant, exhibiting diminished affi njty for skin and greater m e t-
astatic po te ntial (Edelson, 1980) . W hereas in epidermotropic 
CTCL in filtrates nonm alignant m o no nuclea r cell s, in cluding nu-
m erous CDS + T cells, predomin ate , m o re advanced cutaneous 
lesions are composed almost en ti rely of malignant cells (Wood 1'1 ai , 
1991; Bagot eI ai, 1992). T his fLl1ding suggests that disseminatio n of 
CTCL results fi'om the diminished expressio n of tumor anti gens 
andlor a fui lure of the immune respo nse to contain and destroy th e 
malignant ce lls. 
T hi s premise is suppo rted by findings ill a large number of 
leukemic CTCL patients treated with extraco rporea l photochemo-
therapy (Ede lson el ai, 1987; H ea ld e ( ai, 1992), where response to 
treatment is apparently dependent on the presence ofCDS + T cells, 
w hich in crease in number in patients who are in iJlduced remission . 
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radiated tumor. The cytolytic T cells produced tumor 
necrosis factor-a in response to stimulation with 
autologous tumor. The presence of tumor-specific 
cytotoxic T cells recognizing distinctive class I asso-
ciated molecules on cutaneous T-cell lymphoma tu-
mor cells suggests that infiltration of early lesions by 
CD8 cells reflects host immunity to the neoplasm. 
These studies provide the foundation for the devel-
opment of tumor vaccines through the use of cyto-
toxic T cells to isolate and characterize tUlTIOr-aSSo-
ciated cutaneous T-cell lymphoma peptides. Key 
luords: C)'totoxic T celis/imlllllltotlterapyIT-celllelikemialtlllllor-
associated peptides. ] Invest Demwtol107:392-397, 1996 
A comple te response to therapy is m o re likely to occur in those 
patients in whom a res idual CDS pop ulation is present (Hea ld et aI , 
1992). Animal model s of this therapy revea l that the illlmul1o regu-
la tOl)' respo nses gene rated after reinfus iOIl of ph o to treated acti-
vated lymphocytes arc mediated by CD8 -' cytotoxic T lymphocytes 
(Per ez e( nl, 19S9). T hese observ;ltiol1s hav e raised the possibili ty 
that CT L cells bear tumor-specific an tigens associated at the celJ 
surfa ce w ith class I major hi stocompatibili ty m o lecul es. 
Our novel o bservati o n that purified pop ulatio ns of CDS cells 
selectively target auto logous tumor cell s, thro ugh a class I limi ted 
cytolyti c response, w as made possible through two rece nt ad vances: 
o ur ability to isolate .l a rge numbers of CTCL ce lls using highly 
selecti ve m o noclonal an tibodies (Charley 1'1 ai, 1990) and the 
availabili ty of patients respondip g to immuno th e rapy fo r their 
CTCL (Ede lson eI ai, 1987; H eald 1'1 ai, 1992). T he cytotox ic T -cell 
responses are patien t spec ific and can be selectively enhanced by 
in cuba tion with fa ctors released fro m auto logous tumo r cell s. T he 
C D S lines aJso produce tumor necrosis facto r-a (TNF-c~) in a 
tumo l'- specific fas hi on , and this cytokj ne ma y also playa ro le in the 
immune response to CTCL tumor ce lls . 
MATERIALS AND M ETH ODS 
Isolation and P urificatiolJ ofTll1110r altd CDS Cells To isolilte l:u'ge 
numbers of tumor and CD8 cell s, leukocytes were enriched fro m the 
pe ripheral blood of CTCL patients, after in fo rmed consen t (in accordance 
w ith institutional investigational rev iew board po licy), during therapeutic 
leukapherescs. T he lymphocyte population iso lated by flco ll hyp:lque 
Aotation (Boyum, 1968) ro utinely yie lded bl!tween lOR and 10" mononu-
clear leukocytes per pheres is. Excess ceLi s were cryopreserved. Tutllor ceLi s 
were iso la ted with monoclonal antibod ies reactive with the va ri :lble region 
of the (3- o r a - chain (V(~ , V"l of the T-ce ll receptor (T Cell D ia g;nostics, 
Woburn, MA). Approximate ly, 100 X 10" leukocytes/] 00 ILl of R.PMI 
1640 (GIBCO, Gaithersburg, MD) were incubated with 200 ILl of aLSO 
ILg/ ml so lu tio n of the ap propriate all ti-V reg;io ll mo noclonal antibody for 30 
min at 4°C. The cells were washed and re incubated with magnetic sheep 
,lIlti-l11o use Ig bC:lds (D)'nal , Lake Success, NY ; 1 III I of beads -3 
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b e ads/ce ll ) fori h at 4°C on a tube rotator. TUlllo r cd ls tha t had bound 
rnagnetic beads were separa ted by placing the tube in a magnet and allowiug 
the ce ll s to adhe re to the tube wa ll. N egative cell s w ere asp irated and 
reserved fo r C D 8 iso lation. 
The tumor cell s we re re leased from the magnetic ficld. washed. and 
in c ubated overnight at 37"C, in IlPMI 1640 containing 20% feta l bovine 
se rum (GI13CO). aud 5 ug iute ri cukin 7 pCI' rn l (IL-7, GenzYlllc. C am-
bridge, MA) to allow release of the magnetic beads thro ugh modula tio n of 
the surf:l ce receptor. T he beads were removed by magnetic separation. and 
the t Unlor ce ll s w ere cul tured in 111cdia co n ta ining I L-7 . TUll10r ce ll 
recovery va ri ed fro m 4()-70% of the initia l ava il able tumor population. 
Viability was routine ly greater than 95%. as deterrnined by trypan blue 
exclusio n . The tumor negative ce ll s we re in ubated w ith anti-CD8-
conjug ated magneti c beads (Dyna l, Great N eck, NY; 2 m l of C D8 
bcads/65 X lOt. cell s in RPM I 1640. - 4 beads/cell) in a simi la r fa shion to 
tbat d escribed fo r the tulllor cell s. T he DS + cell s w ere incubated in IL-2 
(500 units/ml , Gen zyrne) and IL-7 (5 n g/ ml) in RPMI 1640 / 10'1., human 
A.B se rum overnight to allow removal of the beads . T he recovered ce ll s 
were fi~eed 6'om the re m aillin g beads andrecul turedwithIL-2. IL-7 . and an 
e quivale nt number of y-irrad iated autologous tU l1l o r cell s (1 500 rads , 
Cesium Irradia tor). T he ce Li s we re red with fi'esh m edia and irradiated 
a utOlogous tumor o n a weeki), basis. 13ecause the CTCL patie nts have a 
depleted C D S popula tio n , the CDS ce ll recovery varied depending on the 
initial CD8 count fi'ol11 1 to 4 X 10", per 1 00 X I 0(' le ukocytes processed. 
Viability of the recovered ce ll s was gre;lte r than 95%. 
Phenotypic Analysis To detennine the pu.6ty of the iso lated cell popu la-
tions , m o noclonal antibody phcnotyping was performed as previousl), de-
scribed (Kung ,·t al. 198 1). III b.-icf, 1 X 10" lymphocytes were incubated with 
1 00 p.l of the relevant monoclonal antibod), at the predetennined optimal 
dil ution (generall y 1 :'10 to 1 :40 d il ution of a 1 11Ig per rnl solution of antibody) 
for 30 min at 4°C . T he cells were washed twice and rein cuba ted with a 
fluoresccin-cor\jugated rabbit anti-mollse IgG reagent (1 :40 dilution. C appel , 
Durham . NC) for 30 mill at 4°C. Fluorescence was analyzed by passage 
through a cyto Au orograph (Coul ter, E."cei. Hialeah, FL) . 
Cytotoxicity Assay To de termine the cyto lytic response, purified CDS 
cells were cul tured to r 2- 3 wk and then added to 4 X 10.1• 51 chro miulll 
labeled tumor ce lls/w ell (1 p.C i 51 chJ"Omiurn/ l 0 X 10" ce Li s. I h, 37°C). 
Triplicate we ll s w e re assayed fo r each culture. The plates we re in cuba ted fo r 
6 h at 37°C and then centrifuged. T he supernata nts (100 p.1/ well ) we re 
harvested and counted III " g allllna co un ter. Pe rcen t specific cyto tox-i city 
was calculated by: 
E - BG 
------ X l 00 
100% lysis - BG 
w h e re E = experimen ta l. BG = backgro nnd. and 100% lysis is obta ined by 
detergent lysis. N o nspecifi c reh:ase of 51 chro miulI1 £i'om labeled target cell s 
did not exceed 15"1., of the amo unt of iso to pe re tained in the labeled targets. 
Inhibitio n of cyto toxicity was tes ted by the addition of 1II0nociona i 
antibo d y W6/32 ( 1:10 di lu tio n of culture supern ata nt) . W6/32 (a gift from 
Dr. Pe ter C resswell. Ya le University . N ew Haven , C T) recognizes a 
JTIo nomorphic ep itope expressed 0 11 al l class I molecules. T he antibody or 
JTI urine ascites of the same isotype was incubated w ith 51 ch rol11iul11-lab~lcd 
WHlOr ce ll s. for 3 0 mill at 4°C . T he ce ll s w ere washed and p lated ' IS 
d escribed for the standard assay . 
LiDliting Dilution Isolation of CDS Clones To d ete rmin e w hether 
clonal populatio ns of C D S+ e ffector ce ll s cou ld be o btailled £i'om the 
periphe ral b lood of CTCL pa tients. limiting di lutio ll cultures w e re es tab-
lished by p.lating the D 8 ce ll s at 0.3 ce ll s/ we ll ill a microtiter plate, over 
a feeder layer ofl X 10.1 y-in:adiatedauto logous tUHlo r celis/ well. T he cell s 
were cultured in standard media, and whe n growth became evident 
(a pproximate ly 3 wk) the cells w ere fed on a weekly bas is. Approximately 
30% of the well s showed growth and 8-16 ciones w e re expanded frol1l each 
patie nt. When '1 X 10" cell s w ere obtained per well . the ce ll s w ere 11I0ved 
into larger 2-cc w"cll s and red 0 11 a weekly basis . .In some cases, 1 X 10" ce lls 
co uld be e"-panded to 6 X I 06 cell s after 3 wk of cul ture. 
Co-cultivation of TUl110r Cells with ')I-Irradiated Autologous Tu-
tnor To determiJle if y-irradiated tumor cell s release snbstances tlwt serve 
to sensitize viab le auto logous tumo r cells to cytolys is, tumor ce ll s were 
')I-irradiated and co- cultured at a 1 :'1 ratio w ith autologous tumo r ill 
standard m edia, for 24 h at 37°C. T he co- cul tures we re labe led with 
51 chro mium for usc as target cell s in cy totoxicity assays. 
Concanavalin A Stimulation of Normal Monolluclear Cells To 
determine the specifi city of CD8 c fl:ectors for autologous tumor. no rma l 
mononuclear ce ll s were obta ined b y reserving the cells tI,at rema ined afte r 
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Table 1. Phenotype of Cell Populations Purified From 
Patients with CTCL 
Patien t Cell Populatio n CD3 
AR. MNL 98 
Purified tUI110 l ' - " 
Purifi ed CDS 
C ultured CDS Lille 4 111 0 
55 MNL 95 
Purified tul1lor 
Purified CD8 
C ultured CD8 Line 4 m o 
.IS MNL 83 
Purified tumor 
Puri.fied C DS 
WW MNL 95 
Purified tumor 
Purified C D S 
Monoclonal Antibody 
(% Pos itive Cell s)" 
CD4 CDS V/3.o: 
98 2 92 V(.lSa 
9S 
0 90 
72 
92 2 83 V (.l8. 
98 81 
62 
82 
62 21 47 V f3Sb 
84 
89 5 87 V,,2 
95 94 
S7 
" Da ta represe ll t the percentage o f Auorescell t cells obtnincd by cytoAo urograph 
cV:l l u:ltiOI1 . 
/. Dashes indie'l te ('hat thc pil cnotyping was no t dOll c. 
tumor and CD8 cell dep letion. The ceLIs were cultured fo r 3 d at 2 X 10" 
cells per ml in R.PMI 1640 containing ·15% feta l bovine serum and 40 p.g 
concanava lin A per ml. T he cell s were harvested. washed , and labe led with 
5 1chromium for usc as targets in cytotoxicity assa)'s. 
[.IH)Tbytnidine Uptal{e To dete rmine w hether CD8 ce ll s we re stimu-
lated to divide after exposure to y-irradiated autologous tumor, pro lifera-
tio n assa ys were establi shed. Puritied CD 8 cells (100 p.llwell of2 X 10(' cells 
per m l) were iJl cubated alone wi th KPM I 1640/10% h uman AJ3 serum and 
IL-2 ("100 p.l/ w ell) , or added to 100-p.1 samples of 2 X 10" cell s per ml 
y-irradiated autologous tumor cell s :Ind cultured. for 6 d under 5% CO,. in 
a 37°C incubator. T umor cell s were y-irradiated and incubated alone 
(l 00-p.1 aliquot of a 2 X 10" cells pe r m1 suspensio n) in standard media (100 
p.llwell ). Proliferatio n was monitored by addition of 1 !LC i [3Hlth)~nidin e 
per w ell. for 6 h . T he cells w ere harvested with a PhD-automated cell 
harvester (Cambridge Technology, Cambridge. MA). T he incorporation of 
radiolabel was ev:liuated by counting in a beta liquid scin ti ll ation coumer 
(Packard Instrume nts, Downers Grove, IL) . 
Class I Expression T he level of class I expression w as determined with 
Quantum Simply Cellular microbeads (Flo w Cytomet.ry Standards Corp .. 
San Juan, Puerto luco). T he beads were labeled with anti-class I mo noclo-
nal antibody W6/32 through Fc receptor binding . T he beads w ere t hen 
labeled w ith a secondary fluorescein-co njugated rabbit aJiti -mo llse reagent. 
The beads were ana lyzed in the cytofluorograph and channel numbers were 
assigned an antibody binding capacit), value thro ugh the usc of ti,e 
Q uickcalc software. T his program aLl ows calculation of the number of 
antibody molecules bound to an unknown cell populatio n through com-
parison of the unknown to the bead calibration sample. 
TNF- a ELISA C D S lines were added to y-irrad iatcd auto logous tumo r at 
a 5: ·1 effector-to-target ratio :lI1d cultured for 18 h at 37"C. The supernatants 
were centrifuged t:o remove cell s and d ebris (900 X g) and tested for TNF- a 
concentration. accordin g to the manufacturer's instructions (R &D System s. 
Minneapolis, MN) . 
RESULTS 
Phenotype of the Isolated Cell Populations Cell populatio ns 
isolate d [rom [our CTCL patie nts w e re phe notyped with m o noclo-
nal antibodjes to e nsure that th e tumor cells and the CDS + cell s 
w e re fi:eed o[ contaminatin g cell types and expressed the appropl;-
ate cell surface markers (Table I) . T h e in.iti al p e riphe ra l blood 
phe notype of these patients d e monstrate s t h e marked e:-..--pansio n of 
clonal T cell s, fro111 a normal va lu e of 5% o[ a V 13 + o r V (X + T-cell 
hmu ly to 47- 92%, and d e p letion of t h e CDS + population in three 
patients, from a norma l of25% to 2-5% (Table I). Despite a g reater 
than S5°/') dec rease in the p e rcentage of CDS cells, it was routin e ly 
possib le to recove r and expand sulticient purifi e d CDS cell s to 
p erform the cytotoxicity experiments. In two patients. C D S cell s 
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Figure 1. Tumor-driven proliferation of purified CDS cells. Purified 
tumor ce lls (opell bill's) or C08 ccUs (ltnfcllrr/ /Jill'S) from patiellts SS and AR 
were cultured alone or co-cultivated (solid bill's). Tlesults represent the 
mean :t SO of ~ tb Yl11 idin e uptake in five replicate cultures. 
were phenotyped after 4 mo in cu lture and the majority of the cells 
maintained CDS expression. 
CDS Cell Expansion and Proliferation To demonstrate that 
CD8 cells were stimulated to expand and proliferate by incubation 
with cytokin es and )I-irradiated autologous tumor, the number of 
CD8 cells was monitored over time. CD8 cell s expanded in culture, 
from 2- to 5-fold over a 1-3 wk interval. 
To demonstrate that the addition of -y-irradiated autologous 
tumor in creased the rate of proliferation of isolated CD8 cells, 
uptake of 3H-thymidine was eva luated. As shown in Fig 1, CDS 
cells from patient SS demonstrated an increased prol iferative re-
sponse w hen )I-irradiated autologous tumor was added, in compa,'-
ison to autologous tumor or CD8 cells incuba ted alone . CD8 cells 
isolated from patient AR also demonstrated a pro li ferative response 
to stimulation w ith autologous tum or, altho ugh at a reduced 
magnitude, in comparison to the response of CDS cell s from SS 
(Fig 1). 
Tumor Specific Cytolysis Purified and expanded polyclonal 
CD8 populations were evaluated for their capacity to lyse auto lo-
gous pm-ifwd tumor targets. Polyclona l CD8 lines isolated on three 
occasions, frO I11 patient AR reproducibly lysed autologo us tumor 
cells (Table II). In two experiments, two CDS lines independently 
isolated fi'om patient SS demonstrated 22'X, cytolysis of autologous 
tumor targets. Two polyclonal CD8 liJles independently isolated 
fi'o l11 5S, 1 y later, demonstrated redu ced cytolysis, at a hi gher 
effector to target ratio (Table II) suggesting diminjshed expression 
of tumor antigens. CDS lines establi shed fro m two other patients 
as and WW; Tables II, III) were also cytolytic for their 
auto logous tumor. Specificity of the cytolytic respo nse ofCD8 tin es 
fro m patients AR and SS is presented in Fig 2 and in Table II for 
patients JS and WW. 
In Fig 2, polyclonal CD8 cells from CTCL patient 5S lysed 
autologous tumor targets but did not recognize tumor cells isolated 
from patient AR. that shared the sam e T-cell receptor beta chain 
variable region (V (38<1). In a reciprocal experiment, CDS cell s £i'om 
AR lysed h.is autologous tumor but did not lyse tumor cells isolated 
from patient 55 (Fig 2). In Table II, tumor cells from patient JS 
(V (~S b) were lysed by autologous polyclona l CD8 cells , whereas 
cells from AR were lysed at a low level. Mononuclear cells fi'om 
patient AR, freed from tumor cells, were not recognized by 
polyctonal CDS cells rrom JS. The results demonstrate that effector 
cells that recogn ize autologous tumor are specifically expanded in 
T HE JOU llNAL OF INVESTIGATIVE DER.MATOLOGY 
Table II. Cytotoxicity of CD8 Lines and Clones Isolated 
fr0111 CTCL Patients 
Patient Exp""1 E:T" Target Cytotox icity 
AR n = 3 10: I l~T" 11. 70 :': 2.15 
SS n = 2 5: '1 ST' 22 .00 :t 2.22 
n = 2 9: 1 ST 13.50 :t 1.60 
] S II = 1 '14:1 JST' 13.00 :t 1.14 
RT 4.00 :!: 0.40 
RMNL' 0.00 :t 0.08 
WW n = 3 6:1 WT' 10.00 :!: 1.60 
RB' 0.00 :t 0.0 
,/ Aburcv i ~tio ll s: Exp, number of ex pe rim ents: E:T; cffcctor:ta rgct ratio . 
II Each experim en t rep resents the mea n ± SI) of th ree rcpli t.:.atc Si.ll11plt.:s. Pulyclona.l 
C DS lin es were eva luated nftcr independ ent isol'ltion. 
" RT, ST. J ST. WT: Patients' autologolls W IllOr cells: rlMNL: patient AR's 
1I10 110I1ucl c~'r leukocytes; lill. Alt's EI3V -t r~ n s formcd B cells, 
the polyclollal CD8 population. In add ition, an absence of alloreac-
tivity for patient AR's EB V-trnllsforl11 ed B cell line was demon-
strated in three experiments with patient WW's CD8 lin es (Table 
II). Although the percentage of tumor cells lysed by the au to logous 
CDS lines is re latively small , the resu lts were consistent in separate 
experim ents performed with indepe nden tly isolated CD8 lines 
fro m fo ur difFeren t CTCL patients. 
Because polyclona l CDS cell s arc a heterogeneous population of 
efFectors, cloned populations of CD8 cell s were established so that 
the specificity of the response to autologous tu mor could be studied 
further. 
Tumor Specific Cytolysis Mediated by Cloned CDS Effec-
tors C lon ed CDS cell s from 2 CTCL patients were tested for 
tumor specifiC cytolysis. Twenty-three clones we re obta ined fi'om 
patient AR; 16 clones demonstrated sufFicient growth fo r subse-
q uent testing. When the clones were tested for tumor specific 
cytolysis, 6 clones demonstrated reactivity with autologous tumor 
cell s. Limi ting dilu tion c ultures of patient SS yielded 22 clones, 5 of 
which were fOllnd to be cytotoxic for autologous tUIlIOr. The 
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Figurc 2. Tumor-specific cytotolysis ofpurificd CD81illCS. Purified 
CD8 cells. from patients SS and AK, lyse autologous tumor targets (SS 
tumor, "I'CII u"rs; A R tllmor, IIl1felled 1'lIrs) but do 1I0t lyse tll mor ce lls purified 
fr0111 the other patient. Kesul ts represent the mea n :!: SD of three repljcate 
silIllples. 
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cytolytic response of the clones derived frOI11 patients AR and 55 
are presented in Fig 3a and b. Only 2 of 9 clones evaluated from 
both patients were able to lyse autologous tumor targets, however, 
overnight co-cultivation of the tumor cells with y- irradiated autol-
ogous tumor resulted in restoration of clonal CDS cytolysis. 
Specificity of the enhanced cytolysis induced by co-cultivation 
with autologous y-irradiated tumor but not allogeneic tumor is 
demonstrated i.n Fig 4. Unmodified autologous tumor cells were 
only minimally lysed . Whereas y-irradiation of the tumor cells did 
not increase cytolysis, addition of y-irradiated tumor cells and 
overnigh t co-cultivation resulted in improved lysis. Addition of 
,,-irradiated allogeneic tumor cells and overnight co- cultivation did 
20 
5 
Targets 
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~ Tumor + Irr Aut Tumor 
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EIT 5:1 
Fignre 4. Specificity of the cloned CDS cytolytic response for 
tumor co-cultivated witlt autologous y-irradiated tumor. Autolo-
gous tUlllor is mil~il11ally lysed by CD8 clones (R.9 and S8, OpCII bars). The 
CD8 clones do not lyse -y-irradiated autologous tUHlor (solid bars). Co-
cultivated of autologous tumor with -y-irradiated autologous tumor over-
night (hatched /)ars), but not allogeneic tumor (cross-hatched bmcf) restores 
cytolysis . Clone S14 does not lyse autologous normal lymphocyte con-
canavalin A blasts (striped bar) . T he resu lts represent the mean :!:: SD of three 
replicate samples. 
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Figure 3 . Tumor cytolysis by cloned CDS 
cells frequently requires co-cultivation 
of tumor targets with y-irradiated autol-
ogous tUll1or. Two of nine C DS clones fr0111 
patieJlts All.. (a) and SS <h) lyse llJlmodified 
tumor targets (R T , AR. tUlllor; ST, SS tumor) 
whereas the remainder of the clones te~ted are 
cytolytic for auto logous tumor co-cultivated 
with )I-irradiated tUlllor. The results represent 
the mean ::t SD of three replicate samples. 
not enhance cytolysis. In addition, CDS clone 514 did not lyse 
activated, autologous normal lymphocytes (driven to become blasts 
by concanava lin A stimu lation) indicating that activation of norm al 
cells does not result in increased expression of the relevant target 
molecules. 
Tumor Specific Cytolysis Requires Class I Expression on 
the Target Cells To determine whether the cytolys is was 
targeted to peptides held iJ1 class I molecules on the tumor cells , a 
monoclonal antibody reactive with class r major histocompatibility 
molecules , as a control ilTe levant murine ascites, was added [Q 
block killing. T h e class I monoclona] antibody specifically inhibited 
tumor cytolys is mediated by CD8 lines derived fi'om two patients 
(Fig 5) . 
Class I Expression 011 Cultured CTCL Tw:nor Cells To 
determine whether reduced class I expression on th e tumor cell s 
impaired their ability to sel'Ve as targets, cultured CTCL cells were 
stained w ith the monoclonal anti-class I antibody, W6/32 . T umor 
cells from CTCL patients AR, 5S, and WW expressed between 2 
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c.:c::::J W6/32 
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Figure 5. Blocking of cytolysis of polyclonal CDS lines willi class I 
specific monoclonal antibody. C08 lines from patients AR. and SS lyse 
autologous tumor in the presence of irrelevant mouse ascites (ASC, "pell 
bar). Addition of a monoclonal antibody to class I major histocompatibility 
complex molecules (hatched bar) blocks the cytolysis . The results represent 
the mean ::t SD of three replicate samples. 
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Figure 6. V11riability of class I expression 011 c ultured CTCL tumor 
cells. The number of molecules of class I major histocompatibility com-
plex , detected by monoclonal antibody, varied on tumor cells frOI11 two 
CTCL patients over a 17-d cu lture period, 
and 5.5 X 105 molecules of class IIcel!. Nomlal expression of class 
I is approximately 105 molecules/cell (Bevan, 1984). In Fig 6, the 
ex--pression of class I on the surface of tumor cells from patients AR 
and SS was compared over 2.5 wk of culture. C lass I expression 
varied 011 the cell surface over time. At every time point tested, 
tumor cells from patient SS expressed more molecules of class I 
than tumor cells isolated from patient AR. In five replicate 
determinations, the average class I expression on SS tumor cells 
(X = 3.74 ± 1.79 X 105) was significantly increased (p :S 0.03) 
above the class T expression detected on tumor cells from patient 
AI't (X = 2.37 ± 1.19 X 105), supporting the contention that the 
increased cytolytic response to SS's tumor might re late to i,llcreased 
avai lability of class I-associated tumor peptides. 
TNF-a Production by CDS Lines in Response to CTCL 
Tumor To further characterize the response of CD8 lines to 
autologous tumor, cu lture supernatants frol11 long-term lines were 
ana lyzed after 18 h of stim ulation with autologous tumor. [n Table 
Ill. the cytolytic response of three CDS lines from patient WW was 
compared with the amollnt of TNF-(l' produced. Lines WWl and 
2 were cytolytic for autologous tumor and also secreted TNF-(l' into 
the culture supematant. A non-cytolytic CDS Lin e WW3 produced 
no detectable TNF-a. 
Long-term CD8 lines independently derived from patients AR 
and SS produced stable or in creasing levels ofTNF- a, in response 
to stimulation with autologous ),-irradiated tumor, over a 2 mo 
culture period. Co-cultivation of AR's or SS's CDS lines with 
),-irradiated tumor from the unrelated CTCL patient did not 
stimu late production of detectable levels of TNF-a. When ),-irra-
Table III. Production of TNF-a by CDS Lines 
Patient Exp" E:T" 
WW 1 3:1 
2 7:1 
3 4:1 
An.. 1 1110 5:1 
21110 
SS 'I mo 5:1 
21110 
,/ Abhrcvialions: as in Table II. 
/, D:,shcs I'epresent experi ment Hot don e. 
/' MC:1I1 ::t SO of three determi nati on s. 
Cytotoxcity 
23% :t 2,3 
l S'Yu :t 0.4 
0.5'% :t 0.0 
_"~ 
TNF-a (pg/ml) 
30 
23 
o 
29 :t lS,S' 
47 :t 3.6 
54 :t 11.9 
77 :t 27.3 
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diated tumor or CDS Lines were cultivated alone, no TNF-O' was 
detected. As observed for the cytolysis studies, CDS Lines derived 
from patient SS alw<lys produced higher levels ofTNF-a than CDS 
lines isolated from the other patients (Table III) . 
DISCUSSION 
Tumor-specific immunity mediated by autologous cytotoxic T cells 
is a hallmark of tumor immunity (Young and Lnaba, 1996). T he 
frequency of tumor reactive cytotoxic T cell s. however, has been 
demonstrated to be extremely low and variable (Massocchi el aI, 
1994). This deficit in cytotoxic T-cell precursors m11y result fi'om 
reduced induction due to low expression of re levant tumor epitopes 
on the malignant cells. 
Patients with adult T-cell leukemia, a m.lfignancy of virally 
infected T cells, have cytotoxic T cells capable oflysing autologous 
tumor cells if sufficient epitopes of the vira l protein are displayed on 
the ceU surface (Kannagi el aI, 1993). Although the levels of class I 
molecules were sufficient on the tumor cells, £i'esh ly isolated adult 
T-cell leukemia cells were only minimally lysed by autologous 
cytotoxic T cells ill lIitro. If the tumor cells were cultured with lectin 
or exogenous HTLV-1 tax peptide, the level of cytolysis increased 
substantially. Therefore, escape from immune surveillance in adult 
T-cell leukemia may be mediated by insufficient expression of 
target peptides on the tumor cell surface, despite the presence of a 
functional cytotoxic T-cell component and adequate expression of 
class I molecules. 
Tumor-specific peptides on CTCL cells, presented in class I 
major histocompatibility complex molecules, are derived liOJll 
cytoplasmic antigens processed for cell surface display by the 
endogenous pathway (Rotzschke and Falk, 1991). Endogenously 
synthesized pep tides typica lly 8-10 amino acids in length, bind to 
the class r major histocompatibility complex molecules in the 
endoplasmic reticulum and are transported to the Golgi for export 
to the ce ll surface (Rotzschke and Falk, 1991; Kelly ct aI, 1992). 
Specific CD8 T cells recognize these peptide-class I complexes and 
target the cell for lysis (Massocchi c/ aI, 1994). In this manner, cells 
expressing class I-associated peptides derived £i'om viruses, point 
mutations, or clone specific T-ce ll receptors can be eliminated. 
An immune response to the neoplastic lymphocytes in CTCL has 
not been previously demonstrated . The current studies were made 
possible by the use of family specific monoclonal antibodies (Char-
ley el aI, 1990), which can serve as an almost tumor-specific reagent 
permitting isolation of highly purified popu lations of tumor cells, 
which can be stimulated to proliferate for prolonged periods by the 
cytokine IL-7 (Dalloul et ai, 1992). Expansion and cloning of the 
CDS effector cells has been potentiated by the purified tumor 
stimulus and the observation that cytokines such as IL-2, and IL-7 
promote cytotoxic T cell growth w hil e preserving tumor specificity 
(Lynch and Miller, 1994). 
Our results show that tumor-specific effector cells exist in the 
peripheral blood of CTCL patients despite the re lative depletion of 
the CDS compartment. T hese effectors recognize autologous tu-
mor in a selective fashion and mediate tumor cell death, through 
cytolysis. Therefore, the limited abili ty of the immune system to 
control the spread of CTCL, in these subjects, does not appear to 
result from a deficit in the function of tumor-specific cytotoxic T 
lymphocytes but probably reflects reduced expression of tumor 
peptides on the malignant T cells. 
The cytolysis observed in this system is unlikely to be due to 
natural killer cells because neither resting nor mitogen-ac tivated 
norm31 lymphocytes were lysed while tumor targets were killed. 
Moreover, th e cytolysis was blocked by class I-specific 3ntibody 
and allogeneic tumor was not lysed (Falk et til, 1995) . Therefore, 
the tumor cytolysis observed in these experiments was class I 
targeted, restricted to the tumor population, and not alloreac-
tive. 
The capacity of the tumor cells to be lysed depends on their 
abi li ty to express class 1 histocompatibility molecules that 
present the re levant tumor epitope to the cytotoxic T cells 
(Kannagi e/ aI, 1993; Massocchi et aI , 1994). Our studies of class 
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I expression o n the tum o r cell s rev eal th at th e level varies in 
different patients and at di ffe ren t times on tumor ce lls cul t ured 
from th e same patien t . T um o r ce ll s fro m pa tien t SS , how ever , 
a lways expressed mo re m o lecules of cla ss T than patien t AR. 
Moreover , these cells were always lysed at a hi gher leve l th an 
tumo r cell s isolated fro m AR and CDS lin es fro m SS produ ced 
h igh er amounts o f T N F-a. T hese resul ts sugges t tha t tumor ce ll s 
t h a t expre ss hi gh leve ls o f cla ss I m olecul es have m ore o f these 
m olec ul es fi ll ed w ith the ap propriate pep tid e tha t can be recog-
nized by tum or-specifi c cytotoxic T lymphocytes . 
Whereas the CDS lines were abl e to lyse unmodified tumor ce lls, 
the clo ned cells required the pre-culture of th e tumor targe ts wi th 
a u tologous )I-irradiated tumor. T his res ul t m ay refl ect recogni tion 
by the cloned cells o f specific tumor peptides expressed in a limited 
fashion on the tumor cells. T he polyclon al CDS lines contain a 
varie ty of efFectors so that mul tiple tumor peptides , some o f w l'Lich 
may be m ore prevalent on the tumor surface , are recognized. 
T h ere fore, polyclonal CDS cells w ill be able to lyse tumor ce lls that 
express only low levels o f som e of th e relevant pep tides, because 
e ffectors specific fo r other more prevalent peptides are available . 
Sup po rt for the observation o f diminished cytolysis of tumor 
targe ts by cytotoxic T cells raised against these targets com es fr0111 
th e studies of CD S cells expanded against Epstein B arr vir us 
tran sformed B cell lines . T he C D S cell s fa il ed to lyse these targets 
unless the cells were superinfected w ith recombin an t v;lccinia virus 
expressing the appropriate Epstein Barr virus pro tein or incubated 
w ith the appropri ate peptide epitope (Hill e/ ai , 1995). T hese studies 
d e m o nstrate tha t an tigenic densi ty may de termine whether a target 
cell is susceptible to cyto lys is . 
T herefore , the factor that consistently limited the level o f 
cytolysis m ediated by CDS cells derived frOI11 CTCL patients m ay 
b e a deficit in the tumor population th at resul ts from redu ced class 
I expression of re levant tumor antigen epitopes. C o-cul tiva tion of 
'Y-irradiated cells wi th autologous tumo r m ay provide tran sfer of 
sen sitizing peptides from the radia tion damaged dying tumor cells 
to class I m olecules on the viabl e tumor cells. Support for this 
hypothesis com es £i'om the studi es with adul t T-cell leukemia 
tu m or cells w here exogeno us peptide was able to sensitize tumor 
cells to cytolysis (Kannagi et ai, 1993). 
C D S induced tumOl' ce ll death may be mediated by two m ech-
anism s: necrosis o r apoptosis (Zychlinsky et ai, 1991). T he produc-
tion of T N F- a by tumor stimulated CDS lines indicates that in 
additio n to rapid cytolysis a more prol onged m ethod of tumor cell 
death m ay also be operative. Bindi.ng of T N F- C\' to its recep tor 
results in transduction of a death signal that may require 2-3 d to 
develop. T he T NF-a studies confirm that CDS efl:ec tors are 
triggered in a tumo r-specifi c fas hion. 
Increased T NF-a production has also been described in m <lcro-
p hages isolated fro m CTCL patients undergo ing photopheresis 
(Vowels et ai, 1992). Macropbages are unli kely to contribu te to the 
T NF-a production observ ed i.n our system because highl y purified 
cell popula tions w ere tested and co-purified m3crophages wo uld 
have been deple ted by plastic adherence during the long periods of 
in "itro cultiva tion (1-3 rno) of the isola ted tUlllo r and CDS 
populations. 
Our studi es are an initial step towards isola tion and characteriza-
tion o f the class 1 pep tides importan t for priming the an ti-tumor 
resp onse in CTCL. Potential candidate peptides include retroviral 
a.ntigens such as HTLV-l, produ cts of no rma'! genes that have 
undergone point mutations, or clone-specific T -cell receptor pep-
tides . Unique pep tides in an individual tumo r cell may arise from 
fram e shift mutations that give rise to new segments of a pro te in. 
M utations resulting in new sequences of anun o acids that produce 
novel p eptides and can be p resented by class I m olecules have been 
sh ow n to induce a vigoro us cytotoxic T - cell response (Townsend ei 
ai, 1994) . 
Iden tification of peptide antigens w ill not only add to our 
knowledge of tumor iml11unobio logy in CTCL, but also provide 
infonnation th;lt will he lp in the development of peptide vaccin e 
therapies . Our studies dem onstrate that it sho uld be possible to 
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positively affect the iml11une response in CTCL when the CD S 
componen t is presen t, fun ctional, a.l1d can be expanded w ith 
appropriate stimulation . 
T his ,pork IIIns slIpported b)' N nliOlltl1111slitlltcs ~r H calth c ra ll is R0 1 :CA43 058 
nlld P30-AR 41942. 
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